EE375 Cost Savings and the Opportunity for Expanded Treatment Access with Increased Use of Biosimilar Adalimumab in the United States
Jun 1, 2024, 00:00
10.1016/j.jval.2024.03.671
https://www.valueinhealthjournal.com/article/S1098-3015(24)00786-1/fulltext
Title :
EE375 Cost Savings and the Opportunity for Expanded Treatment Access with Increased Use of Biosimilar Adalimumab in the United States
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(24)00786-1&doi=10.1016/j.jval.2024.03.671
First page :
Section Title :
Open access? :
No
Section Order :
10145